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Abstract: Raloxifene is a non-steroidal selective estrogen-receptor modulator (SERM) which 
is used for prevention and treatment of postmenopausal osteoporosis. Raloxifene decreases the 
incidence of vertebral fractures by 30%–50% in postmenopausal women with osteoporosis but 
has not been shown to decrease the incidence of hip fractures or other non-vertebral fractures. 
At the present time, estrogen-replacement therapy and bisphosphonate treatment are the only 
medical treatments that are proven to prevent hip fractures with the exception of vitamin D and 
calcium replacement, which has been shown to prevent hip fractures in elderly individuals and 
nursing home residents. Raloxifene has been shown to have additive effects on bone turnover 
and bone mineral density (BMD) when used along with alendronate and teriparatide. Raloxifene 
could have a role in renal failure as it has been shown to increase BMD of the vertebra over 1 
year of therapy. Raloxifene is as effective as tamoxifen in reducing the risk of invasive breast 
cancer. The increased incidence of venous thromboembolism is the main concern of raloxi-
fene therapy and previous history of venous thromboembolism is a contraindication for use of 
raloxifene. Raloxifene has a role in treatment of vertebral osteoporosis in older women. The 
decision to use raloxifene should be based on evaluation of fracture risk and on potential other 
beneﬁ  ts than fracture reduction along with consideration of side effects.
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Introduction
Raloxifene is a nonsteroidal selective estrogen-receptor modulator (SERM) which has 
been marketed for use in prevention and treatment of postmenopausal osteoporosis. 
One of the consequences of the Women’s Health Initiative has been increased inter-
est in the SERMs, because of the potential to retain most of the beneﬁ  cial effects of 
estrogen while avoiding some of the adverse effects (Lawrence Riggs and Hartmann 
2003). Raloxifene binds to estrogen-receptors, with estrogen agonistic effects in some 
tissues and estrogen antagonistic effects in others. In the last few years a number of 
clinical studies have been published on the effects of raloxifene on osteoporosis, the 
risk of invasive breast cancer and cardiovascular diseases. There are a number of other 
SERMS currently under investigation but raloxifene is the only SERM currently on 
the market for osteoporotic fractures (Vogelvang et al 2006). Below is a review of the 
effects of raloxifene in some target tissues, results of clinical trials, along discussion 
of the usefulness of raloxifene in the treatment of osteoporosis in older women.
Mechanisms of action
There are three interactive mechanism that explain the pharmacology of SERMs: 
Differential estrogen-receptor expression in a given target tissue, differential estrogen-
receptor conformation on ligand binding and differential expression and binding to 
the estrogen-receptor of coregulator proteins (Lawrence Riggs and Hartmann 2003). 
There are two main types of estrogen receptors α and β. The α-receptor is mainly an Clinical Interventions in Aging 2008:3(1) 46
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activator and β-receptor inhibitor. The SERMs bind to both 
receptors, functioning as pure antagonist when binding to 
β-receptors and as a partial agonist when binding to the 
α-receptor. The different action of the individual SERM 
depends on coregulatory proteins and their ability to recruit 
coactivators. Estrogenic activation inhibits osteoclasts and 
thereby reduces the bone resorption by osteoclasts that 
restores the balance between bone formation and bone resorp-
tion (Sarkar et al 2002).
Effects of raloxifene on bone
Raloxifene decreases the markers of bone turnover by 
30%–40% after 1 year and increases bone density at several 
scanning sites by 2%–3% after 3 years in postmenopausal 
women with osteoporosis (Delmas et al 1997). Raloxifene 
decreases the incidence of vertebral fractures by 30%–50% 
(Figure 1) but does not decrease the incidence of hip frac-
tures or other nonvertebral fractures (Ettinger et al 1999). 
By contrast, estrogen reduces vertebral and hip fractures 
rate by 34% over average of 5.2 years of therapy (Anderson 
et al 2002). Studies that have looked at bone mineral den-
sity (BMD), bone architecture and bone turnover suggest 
that estrogen is more effective antiresorptive agent than 
raloxifene (Prestwood et al 2000). Raloxifene increases 
BMD at the hip but studies have not shown decrease in any 
non-vertebral fracture. Bisphosphonate therapy decreases 
vertebral fractures by 48% (Liberman et al 1995) only 
slightly more than raloxifene therapy does and decreases hip 
fracture incidence by 30%–50% in postmenopausal women 
with osteoporosis (Black et al 1996; McLung et al 2001). 
Bisphosphonates increase bone mineral density (4%–9%) 
considerably more than raloxifene or estrogen-replacement 
therapy (2%–3%) does (Black et al 1996). This difference in 
bone mineral density increases is not reﬂ  ected in decrease 
in vertebral fractures It has been postulated that this dis-
crepancy in effects of bone mineral density and vertebral 
fracture prevention is due to the normalization of high bone 
turnover in cancellous bone by raloxifene and prevention 
of microarchitectural disruption which leads to reduction 
in vertebral fracture rates. It has been suggested that only 
low therapeutic threshold is needed to prevent osteoclasts 
from perforating the trabecular plates and therefore reduce 
fractures of cancellous bone. Stronger antiresorptive agents 
would be needed for effects on cortical bone such as the 
Figure 1 Reduction in new vertebral fractures among 6828 women who completed the study. Reproduced with permission from Barrett-Connor E, Grady D, Sashegyi A, 
et al 2002. Raloxifene and cardiovascular events in osteoporotic postmenopausal women. Four year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) 
randomized trial.  JAMA, 284:847–57. Copyright © 2002 American Medical Association.Clinical Interventions in Aging 2008:3(1) 47
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hip (Sarkar et al 2002). At the present time, adequate 
vitamin D and calcium supplements (Riggs and Melton 
2002), estrogen-replacement therapy (Anderson et al 2004), 
and bisphosphonate treatment (Black et al 1996; McLung 
et al 2001) are the only medical treatments that are proven 
to prevent hip fractures. However, studies on the effect of 
raloxifene in women older than 70 who are at the greatest 
risk of hip fractures are not availabe. Raloxifene has been 
shown to have additive effects on bone mineral turnover and 
BMD when used with alendronate (Bischoff-Ferrari et al 
2005) and teriparatide (Johnell et al 2002) but these studies 
have not lasted long enough to show fracture reduction.
Effects on breast cancer
Raloxifene has anti-estrogenic effects on breast tissue, as 
tamoxifen does. The Multiple Outcomes of Raloxifene Eval-
uation (MORE) trial, where 7705 postmenopausal women 
with osteoporosis were randomized to raloxifene or placebo, 
demonstrated a 76% reduction of invasive breast cancer over 
4 years (Cummings et al 1999). In the Raloxifene use for the 
Heart (RUTH) trial where 10,101 postmenopausal women 
with either coronary heart disease or multiple risks for coro-
nary heart disease were randomized to raloxifene or placebo, 
there was a 44% relative reduction in invasive breast cancer 
over median of 5.6 years (Barrett-Connor 2006). Tamoxifen 
has demonstrated efﬁ  cacy for treatment and prevention of 
estrogen-receptor positive breast cancer. The National Surgi-
cal Adjuvant Breast and Bowel Project Study of Tamoxifen 
and Raloxifene (NSAP STAR P-2) trial compared the effect 
of tamoxifen versus raloxifene over 5 years on invasive breast 
cancer incidence in 19,747 women at increased risk of breast 
cancer (Villareal et al 2001). Raloxifene was as effective 
as tamoxifen in reducing the risk of invasive breast cancer. 
Raloxifene had lower incidence of thromboembolic events, 
and cataracts and similar effects on other cancers, fractures, 
ischemic heart disease, and stroke.
Effects on the genitourinary tract
Raloxifene does not stimulate the growth of the endometrium 
nor the vaginal mucosa (Kannus et al 2000). Therefore raloxi-
fene would not be useful for either treating postmenopausal 
estrogen deﬁ  ciency symptoms of the lower urinary tract or 
vagina-like dyspareunia, frequency of urination, urinary tract 
infections, or urinary incontinence. Tamoxifen as estrogen has 
been related to endometrial cancer (2.5-fold increase). The 
STAR P-2 trial demonstrated increased incidence of endome-
trial cancer in the tamoxifen group compared with raloxifene 
but without statistical signiﬁ  cance (Vogel et al 2006).
Effects on cardiovascular 
risk factors
Raloxifene favorably alters biochemical markers of cardio-
vascular risk by decreasing LDL-cholesterol, ﬁ  brinogen, and 
lipoprotein (a), and by increasing HDL2-cholesterol without 
raising triglycerides. In contrast to hormone replacement 
therapy, raloxifene has no effect on HDL-cholesterol and 
PAI-1 and a lesser effect on HDL2-cholesterol and lipopro-
tein (a) (Walsh et al 1998). Do these favorable biochemical 
effects mean protection against cardiovascular disease? 
In a secondary analysis of the MORE trial, with women 
with increased risk of cardiovascular risk, cardiovascular 
events were signiﬁ  cantly reduced (Barrett-Connor 2002). 
These results were not conﬁ  rmed in the RUTH trial where 
10,101 postmenopausal women at risk for cardiovascular 
diseases were randomized to raloxifene versus placebo 
(Barrett-Connor 2002). Raloxifene was neither associated 
with increased nor decreased cardiovascular event. Consider-
ing death rates in the RUTH trial, there was a slight signiﬁ  -
cant increase of fatal strokes (but not stroke overall) in the 
raloxifene group which was offset by a signiﬁ  cant decrease 
in non-cancer and non-cardiovascular deaths in the raloxifene 
group (Barrett-Connor 2002). While these results are not 
necessarily true it is wise to consider high risk of stroke a 
relative contraindication to raloxifene therapy. On the other 
hand, the presence of ischemic heart disease is neither an 
indication nor a contraindication for raloxifene therapy.
Age consideration
The studies on raloxifene include women who are post-
menopausal at a mean age of 65–67 (SD 5–7 years) despite 
women up to 80 years of age being enrolled (Delmas et al 
1997; Barrett-Connor 2006). Observation time ranged from 3 
years to 6 years, meaning most of the women are middle aged 
or young-old. Therefore the results apply mainly to middle 
aged or young-old women rather than old and frail women 
who are the usual clients of geriatricians. In these studies, 
however, there are women with cardiovascular disease 
or risk factors for cardiovascular disease, osteoporosis or 
increased risk of breast cancer. Such increased risk of poor 
outcome characterizes the health problems of older people 
in general, making the results somewhat more applicable 
to older women. There are a few studies that have looked 
at older, frailer women and women in nursing homes. Only 
vitamin D supplements and hip protectors have been shown 
to be effective to prevent hip fractures in nursing homes 
(Kannus et al 2000; Bischoff-Ferrari et al 2005). A study 
on the effect of raloxifene on markers of bone turnover in Clinical Interventions in Aging 2008:3(1) 48
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women living in a long term care facility (mean age 84) 
demonstrated comparable efﬁ  cacy in decreasing bone turn-
over as in younger women (Hansdóttir et al 2004). Alendro-
nate (Greenspan et al 2002) and estrogen replacement therapy 
(Stevenson et al 2005) increase BMD of both hip and vertebra 
and decrease bone turnover in women living in long-term 
care facilities and frail elderly women. Risedronate has been 
shown to be effective in women up to the age of 80 but was 
not effective in older women who were assigned to treatment 
based on falls risk but not because of osteoporosis (McClung 
et al 2001). That does not mean it is not useful in women 
older than 80, it means therapy of osteoporosis should be for 
those who have osteoporosis, falls risk is another entity that 
needs to be evaluated and treated according to the relevant 
literature. It is likely that these treatments have identical 
effects on bone in the oldest and frailest age group but other 
aspects need to be taken into consideration when deciding 
how to prevent fractures such as falls risk, mobility, nutrition, 
comorbidity, and altered drug metabolism.
The use of raloxifene 
in older women
Osteoporosis
Prevention and treatment of vertebral osteoporosis is the main 
indication for raloxifene use. Osteoporosis is common in old 
age and osteoporotic fractures reach epidemic proportion 
in the highest age groups (Figure 2) especially in nursing 
homes. Incidence of 10% fracture rate in one year in a nursing 
home has been reported (Chandler et al 2000). Osteoporosis 
should be taken seriously and treated aggressively just as 
any other health problem. Fractures, both vertebral and and 
non-vertebral have a large impact on quality of life (Sarkar 
et al 2002). Oral vitamin D supplementations between 
700–800 IU a day reduce the risk of hip and non-vertebral 
fractures in ambulatory and institutionalized elderly person 
(Bischoff-Ferrari 2005)). Vitamin D deﬁ  ciency is common in 
winter in northern latitudes, especially in those who cannot go 
outside and needs to be replaced (Steingrimsdóttir et al 2005). 
Every older individual should be advised upon adequate 
vitamin D and calcium intake. Raloxifene is a cost effective 
preventive treatment of osteoporosis in women 50–80 years 
old irrespective of severity of osteoporosis (Stevenson et al 
2005). The cost of a quality-adjusted life year (QALY) is esti-
mated at £20,000–31,000, which is considered reasonable. 
These effects assume no effect on hip fractures and are largely 
driven by the reduction of breast cancer. In the older age 
groups where hip fractures are more prevalent, bisphospho-
nates (alendronate and risedronate) are more cost effective 
treatment than raloxifene with QALY of less than £20,000 
in women at high risk of a fracture but the cost is higher in 
younger women or in those without previous fractures. The 
most important reason women cannot take bisphosphonates 
is because of compliance, gastrointestinal symptoms and 
occasionally musculoskeletal pain and renal impairment 
(Emkey et al 2006). In my practice there are a number of 
women who need nurse’s assistance to take medication and 
once a week special visit for a weekly bisphosphonate would 
add considerably to the cost of therapy. The availability of a 
monthly dose is now an attractive choice (Reid et al 2002). 
Parenteral therapy is possible for those who cannot tolerate 
bisphosphonates by mouth (Ersoy 2006). Raloxifene is an 
alternative for vertebral fracture prevention and is easy to 
administer. It is given once a day and can be given with other 
Figure 2 Annual incidence of osteoporotic fracture in females by site. Reproduced with permission from Stevenson M, Lloyd M, De Nigris E, et al. 2005.   A systematic review 
and economic evaluation of alendronate, etidroneate, risedronate, raloxifene and teriparatide of the prevention and treatment of postmenopausal osteoporosis. Health Technol-
ogy Assessment, 9:1–160. Copyright © 2005 NIHR.Clinical Interventions in Aging 2008:3(1) 49
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regular medications and has the added beneﬁ  t of reduction 
of hormone postive breast cancer. Raloxifene has been used 
along with other drugs for osteoporosis, such as alendronate 
(18) and teriparatide (Deal et al 2005). In both cases, raloxi-
fene has an additive effect on BMD in both hip and vertebra 
along with increased reduction of bone turnover. Renal 
failure complicates the treatment of osteoporosis (Ersoy 
2006). Bisphosphonates and teriparatide are in general not 
recommended in renal failure if creatinine clearance is less 
than 30–35 mL/min. Raloxifene might have a role in renal 
failure as it has been shown to increase BMD of the vertebra 
after one year of therapy (Hernandez et al 2003). It is metabo-
lized by liver and is safe to administer in renal failure. The 
presence of nephrotic syndrome should, however, be looked 
upon as a contraindication to raloxifene due to increased risk 
of venous thrombosis. More studies are needed for fracture 
prevention in renal failure for any agent.
Strontium ranelate and teriparatide are other alterna-
tiveson the market for osteoporosis and fracture prevention 
which have shown reduction of fractures (Neer et al 2001; 
Reginster et al 2005).
Reduction of risk of breast cancer
When choosing an agent for treatment of any health prob-
lems, other effects have to be taken into consideration. The 
secondary beneﬁ  t of raloxifene is prevention of hormone 
positive breast cancer. There are no current guidelines on 
primary prevention of breast cancer so raloxifene for that 
use is not at present indicated for that use. The yearly overall 
risk of newly diagnosed breast cancer is one in 500 for a 
70-year-old woman and 1 in 400 for an 80-year-old woman, 
that would be approximately 1 in 40–50 over 10 years and 1 
in 20–25 over 20 years (McPherson et al 2000). The fact that 
while breast cancer comprises 20% of mortality for younger 
women, other disease such as cardiovascular diseases can be 
attributed to a majority of deaths for older women and breast 
cancer only to a small percentage (Cummings et al 1993). 
The issue of treatment of invasive breast cancer should be 
referred to a specialist in most cases and therefore beyond 
the scope of this article. Women with a breast tumor who do 
not desire neither a work up or anti-cancer treatment such as 
surgery, radiation nor chemotherapy, could be offered raloxi-
fene with the added beneﬁ  t of vertebral fracture prevention. 
Tamoxifen is effective in reducing recurrences of hormone 
positve breast cancer as a sole treatment (Cummings et al 
1993) and raloxifene can be expected to do the same. Such 
situations arise in nursing homes or in case of very frail 
old women.
Increase in risk of thromboembolic 
events
The increased incidence of venous thromboembolism is the 
main concern of raloxifene therapy and previous history 
of venous thromboembolism is a contraindication for use 
of raloxifene. Old age is risk factors for thromboembolic 
events reaching approximately 0.5% a year at the age of 
80 (Ageno et al 2006). Raloxifene treatment increases 
the risk 1.5–3.0 times which would mean absolute risk of 
0.75%–1.5% a year (Ettinger et al 1999; Riggs 2000). Over 
5 years that could mean 3%–7% risk and over 10 years of 
therapy up to possibly 15% likelihood of a thrombosis. 
Other risk factors are obesity, tendency for thrombosis, 
cancers, inﬂ  ammatory diseases, and surgery. Hospital stay 
with immobility, stroke, heart failure, respiratory failure, 
sepsis or inﬂ  ammation, increase the risk considerably. It is 
wise to use active thromboprophylaxis and stop raloxifene 
treatment during the hospital stay until the patient is fully 
mobile for these conditions.
Conclusion
The decisions to treat osteoporosis for fracture prevention 
needs to be discussed with the individual and the fracture risk 
needs to be taken into account along with other beneﬁ  ts and 
risks of treatment. Every older individual should be advised 
upon adequate calcium and vitamin D replacement. Individu-
als at increased risk of fracture either because of osteopenia 
or osteoporosis should be evaluated for further treatment. 
Raloxifene is an effective treatment for prevention of verte-
bral fractures in postmenopausal women. Raloxifene has the 
added beneﬁ  t of prevention hormone positive breast cancer 
but increases risk of venous thromboembolism. Raloxifene 
could be used as well as an additive agent in postmenopausal 
women with severe osteoporosis.
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